AU2014364520B2 - Methods and assays relating to circulating tumor cells - Google Patents

Methods and assays relating to circulating tumor cells Download PDF

Info

Publication number
AU2014364520B2
AU2014364520B2 AU2014364520A AU2014364520A AU2014364520B2 AU 2014364520 B2 AU2014364520 B2 AU 2014364520B2 AU 2014364520 A AU2014364520 A AU 2014364520A AU 2014364520 A AU2014364520 A AU 2014364520A AU 2014364520 B2 AU2014364520 B2 AU 2014364520B2
Authority
AU
Australia
Prior art keywords
protein
gene
level
family
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014364520A
Other languages
English (en)
Other versions
AU2014364520A1 (en
Inventor
Daniel A. Haber
Shyamala Maheswaran
David T. TING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of AU2014364520A1 publication Critical patent/AU2014364520A1/en
Application granted granted Critical
Publication of AU2014364520B2 publication Critical patent/AU2014364520B2/en
Priority to AU2020200114A priority Critical patent/AU2020200114B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014364520A 2013-12-20 2014-12-18 Methods and assays relating to circulating tumor cells Active AU2014364520B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020200114A AU2020200114B2 (en) 2013-12-20 2020-01-07 Methods and assays relating to circulating tumor cells

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361918816P 2013-12-20 2013-12-20
US61/918,816 2013-12-20
US201461937883P 2014-02-10 2014-02-10
US61/937,883 2014-02-10
PCT/US2014/071169 WO2015095527A1 (en) 2013-12-20 2014-12-18 Methods and assays relating to circulating tumor cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020200114A Division AU2020200114B2 (en) 2013-12-20 2020-01-07 Methods and assays relating to circulating tumor cells

Publications (2)

Publication Number Publication Date
AU2014364520A1 AU2014364520A1 (en) 2016-07-07
AU2014364520B2 true AU2014364520B2 (en) 2020-01-02

Family

ID=53403695

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014364520A Active AU2014364520B2 (en) 2013-12-20 2014-12-18 Methods and assays relating to circulating tumor cells
AU2020200114A Active AU2020200114B2 (en) 2013-12-20 2020-01-07 Methods and assays relating to circulating tumor cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020200114A Active AU2020200114B2 (en) 2013-12-20 2020-01-07 Methods and assays relating to circulating tumor cells

Country Status (6)

Country Link
US (2) US10900083B2 (enExample)
EP (2) EP3865144A1 (enExample)
JP (3) JP6599334B2 (enExample)
CN (2) CN111729090A (enExample)
AU (2) AU2014364520B2 (enExample)
WO (1) WO2015095527A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014364520B2 (en) * 2013-12-20 2020-01-02 The General Hospital Corporation Methods and assays relating to circulating tumor cells
CN115184315A (zh) 2016-04-15 2022-10-14 伯克利之光生命科技公司 用于坞内测定的方法、系统和试剂盒
US10858649B2 (en) 2016-09-15 2020-12-08 Augmenta Bioworks, Inc. Immune repertoire sequence amplification methods and applications
US10266793B2 (en) 2016-09-30 2019-04-23 Novaflux, Inc. Compositions for cleaning and decontamination
WO2018084836A1 (en) * 2016-11-02 2018-05-11 Development Center For Biotechnology Anti-tmcc3 immunoconjugates and uses thereof
KR102583603B1 (ko) * 2017-03-16 2023-10-05 유니베르시테 리브레 드 브룩크젤즈 Cd321 마커의 발현을 기반으로 한 순환 종양 세포의 검출, 정량 및/또는 단리
CN106939340A (zh) * 2017-03-31 2017-07-11 哈尔滨医科大学 一种与肺腺癌转移及预后相关的分子标记物及其应用
CN109554450A (zh) * 2017-09-25 2019-04-02 上海艾壳基因技术有限公司 循环肿瘤细胞捕获并进行全基因转录组检测的方法
EP3721209B1 (en) 2017-10-15 2024-02-07 Berkeley Lights, Inc. Methods for in-pen assays
CN109988825B (zh) * 2017-12-29 2023-03-10 杭州莲和医学检验所有限公司 构建细胞全转录本扩增产物的方法及其应用
SG11202006441SA (en) * 2018-01-15 2020-08-28 Epiaxis Therapeutics Pty Ltd Agents and methods for predicting response to therapy
EP3775133B1 (en) * 2018-04-03 2024-10-09 Novaflux, Inc. Cleaning composition with superabsorbent polymer
US20210318335A1 (en) * 2018-08-28 2021-10-14 Duke University Biomarkers, compositions, and methods for diagnosing and treating subjects exposed to protein/heparin complexes
JP2022500029A (ja) * 2018-09-11 2022-01-04 ザ ジェネラル ホスピタル コーポレイション 肝臓疾患を検出する方法
US11662341B2 (en) 2018-10-10 2023-05-30 Augmenta Bioworks, Inc. Methods for isolating immune binding proteins
CN109266714A (zh) * 2018-10-12 2019-01-25 广州医科大学 一种循环肿瘤细胞的检测方法
US20220000817A1 (en) * 2018-11-01 2022-01-06 Academia Sinica Prognosis and treatment of metastatic cancer
CN113785050B (zh) * 2019-04-30 2025-03-14 加利福尼亚大学董事会 使用广谱纳米颗粒实现基因组检测
CN110229903A (zh) * 2019-06-25 2019-09-13 台州市立医院 Podn作为诊断甲状腺癌的分子标志物
KR102699848B1 (ko) * 2019-07-29 2024-08-29 서울대학교병원 암 진단을 위한 바이오마커
US12064495B2 (en) 2019-10-03 2024-08-20 Protegera, Inc. Oral cavity cleaning composition, method, and apparatus
WO2021067872A1 (en) 2019-10-03 2021-04-08 Novaflux, Inc. Oral cavity cleaning composition, method, and apparatus
JP7475626B2 (ja) * 2019-11-01 2024-04-30 学校法人近畿大学 バイオマーカーを用いた哺乳動物胚の選別方法
CN111073980B (zh) * 2020-01-02 2020-10-27 牡丹江医学院 一种肝内胆管细胞癌的诊断方法及诊断试剂盒
CN114058699B (zh) * 2020-07-31 2023-04-07 中国科学院上海营养与健康研究所 Ppdpf在胰腺癌诊断及药物制备中的应用
JP7477872B2 (ja) * 2020-09-30 2024-05-07 国立大学法人大阪大学 癌に関連する新規バイオマーカー
CN112992266B (zh) * 2021-02-05 2021-09-21 深圳裕康医学检验实验室 一种评估肿瘤免疫耗竭状态的方法、装置和存储介质
CN112852816B (zh) * 2021-02-25 2023-03-31 中国医科大学附属盛京医院 一种针对dnajb11基因的靶向抑制剂及其应用
JP7732841B2 (ja) * 2021-10-14 2025-09-02 株式会社三共 遊技機
JP7732840B2 (ja) * 2021-10-14 2025-09-02 株式会社三共 遊技機
JP7732842B2 (ja) * 2021-10-14 2025-09-02 株式会社三共 遊技機
JP7732839B2 (ja) * 2021-10-14 2025-09-02 株式会社三共 遊技機
JP7732843B2 (ja) * 2021-10-14 2025-09-02 株式会社三共 遊技機
CN114875135B (zh) * 2021-12-25 2023-01-10 济宁医学院 Ogn基因作为生物标志物在制备诊断胰腺癌的试剂盒中的应用
CN114317747A (zh) * 2021-12-28 2022-04-12 深圳市人民医院 Swi5在结肠癌的预后中的应用
CN114317775B (zh) * 2022-01-12 2023-06-30 中国人民解放军军事科学院军事医学研究院 一种NCOA4的RNA m6A修饰作为γ射线辐射标志物的应用
WO2023178264A2 (en) * 2022-03-16 2023-09-21 Empirico Inc. Treatment of hgfac related diseases and disorders
CN115058516A (zh) * 2022-04-28 2022-09-16 北京大学第三医院（北京大学第三临床医学院） 用于上皮性卵巢癌诊断的标志物及其应用
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
CN116577506A (zh) * 2023-04-26 2023-08-11 苏州大学 一种鉴别hcc亚型的标志物hnf1b及dphcc体外模型的构建
CN116694756A (zh) * 2023-06-28 2023-09-05 复旦大学附属华山医院 家族性成人肌阵挛癫痫的诊断标志物和应用
WO2025059345A1 (en) * 2023-09-14 2025-03-20 Empirico Inc. Treatment of hgfac related diseases and disorders
CN118858637B (zh) * 2024-09-26 2024-12-17 四川大学华西医院 一种用于捕获循环肿瘤细胞的标志物组及试剂盒与装置

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006029A1 (en) * 2001-07-13 2003-01-23 The University Of Sydney Method of inducing apoptosis in cancer cells
WO2006089091A2 (en) * 2005-02-18 2006-08-24 Memorial Sloan-Kettering Cancer Center Methods for detecting minimum residual disease
WO2009051734A1 (en) * 2007-10-17 2009-04-23 The General Hospital Corporation Microchip-based devices for capturing circulating tumor cells and methods of their use
WO2011112903A2 (en) * 2010-03-11 2011-09-15 Board Of Regents, The University Of Texas System Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
US20120009582A1 (en) * 2010-07-07 2012-01-12 The Regents Of The University Of Michigan Diagnosis and treatment of breast cancer
WO2013109944A1 (en) * 2012-01-18 2013-07-25 The Trustees Of The University Of Pennsylvania Methods for assessing risk for cancer using biomarkers
WO2013117705A1 (en) * 2012-02-09 2013-08-15 Var2 Pharmaceuticals Aps Targeting of chondroitin sulfate glycans
WO2013134649A1 (en) * 2012-03-09 2013-09-12 Verastem, Inc. Biomarkers for cancer stem cells and related methods of use

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622871A (en) 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4135884A (en) 1977-08-29 1979-01-23 Shen James T Gamma stick
US4305924A (en) 1979-08-08 1981-12-15 Ventrex Laboratories, Inc. Method and apparatus for performing in vitro clinical diagnostic tests using a solid phase assay system
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US4444880A (en) 1982-07-27 1984-04-24 Syva Company Periodate removal of ascorbate interference in dipsticks for immunoassays
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
EP1248112A3 (en) 1987-04-27 2004-08-25 Inverness Medical Switzerland GmbH Immunochromatographic specific binding assay device
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
CA1340032C (en) 1987-06-24 1998-09-08 Jim Haralambidis Lucleoside derivatives
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
JPH03503894A (ja) 1988-03-25 1991-08-29 ユニバーシィティ　オブ　バージニア　アランミ　パテンツ　ファウンデイション オリゴヌクレオチド　ｎ‐アルキルホスホラミデート
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
DE69034150T2 (de) 1989-10-24 2005-08-25 Isis Pharmaceuticals, Inc., Carlsbad 2'-Modifizierte Oligonukleotide
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
CA2029273A1 (en) 1989-12-04 1991-06-05 Christine L. Brakel Modified nucleotide compounds
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5852188A (en) 1990-01-11 1998-12-22 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
DK0455905T3 (da) 1990-05-11 1998-12-07 Microprobe Corp Dipsticks til nukleinsyrehybridiseringsassays og fremgangsmåde til kovalent immobilisering af oligonukleotider
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
WO1992002258A1 (en) 1990-07-27 1992-02-20 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
PT98562B (pt) 1990-08-03 1999-01-29 Sanofi Sa Processo para a preparacao de composicoes que compreendem sequencias de nucleo-sidos com cerca de 6 a cerca de 200 bases resistentes a nucleases
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
EP0549686A4 (en) 1990-09-20 1995-01-18 Gilead Sciences Inc Modified internucleoside linkages
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
GB9100304D0 (en) 1991-01-08 1991-02-20 Ici Plc Compound
DE69229334T2 (de) 1991-01-11 1999-12-16 Quidel Corp., San Diego Einstufiges querfluss analysenverfahren und ein darin verwendeter nichtsaugfähiger träger
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
EP0538194B1 (de) 1991-10-17 1997-06-04 Novartis AG Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US6277603B1 (en) 1991-12-24 2001-08-21 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DK1695979T3 (da) 1991-12-24 2011-10-10 Isis Pharmaceuticals Inc Gappede modificerede oligonukleotider
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
DE4203923A1 (de) 1992-02-11 1993-08-12 Henkel Kgaa Verfahren zur herstellung von polycarboxylaten auf polysaccharid-basis
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
EP0691968B1 (en) 1993-03-30 1997-07-16 Sanofi Acyclic nucleoside analogs and oligonucleotide sequences containing them
HU9501974D0 (en) 1993-03-31 1995-09-28 Sterling Winthrop Inc Oligonucleotides with amide linkages replacing phosphodiester linkages
DE4311944A1 (de) 1993-04-10 1994-10-13 Degussa Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
US5955591A (en) 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
US6015886A (en) 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
JPH09507836A (ja) 1993-11-16 1997-08-12 ジンタ・インコーポレイテッド 非ホスホネート・ヌクレオシジル間結合と混合したキラリティー的に純粋なホスホネート・ヌクレオシジル間結合を有する合成オリゴマー
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US6608035B1 (en) 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
EP0813539B1 (en) 1995-03-06 2006-05-24 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6444423B1 (en) 1996-06-07 2002-09-03 Molecular Dynamics, Inc. Nucleosides comprising polydentate ligands
US6639062B2 (en) 1997-02-14 2003-10-28 Isis Pharmaceuticals, Inc. Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6524681B1 (en) 1997-04-08 2003-02-25 3M Innovative Properties Company Patterned surface friction materials, clutch plate members and methods of making and using same
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6528640B1 (en) 1997-11-05 2003-03-04 Ribozyme Pharmaceuticals, Incorporated Synthetic ribonucleic acids with RNAse activity
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US7273933B1 (en) 1998-02-26 2007-09-25 Isis Pharmaceuticals, Inc. Methods for synthesis of oligonucleotides
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US7045610B2 (en) 1998-04-03 2006-05-16 Epoch Biosciences, Inc. Modified oligonucleotides for mismatch discrimination
US6531590B1 (en) 1998-04-24 2003-03-11 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligonucleotide compounds
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6867289B1 (en) 1998-10-26 2005-03-15 Board Of Regents, The University Of Texas Systems Thio-modified aptamer synthetic methods and compositions
US6465628B1 (en) 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
KR100782896B1 (ko) 1999-05-04 2007-12-06 엑시콘 에이/에스 Ｌ-리보-ｌｎａ 유사체
US6593466B1 (en) 1999-07-07 2003-07-15 Isis Pharmaceuticals, Inc. Guanidinium functionalized nucleotides and precursors thereof
US6147200A (en) 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
IL148304A0 (en) 1999-09-10 2002-09-12 Geron Corp Oligonucleotide n3'-p5' thiophosphoramidates, their synthesis and use
AU2001227965A1 (en) 2000-01-21 2001-07-31 Geron Corporation 2'-arabino-fluorooligonucleotide n3'-p5'phosphoramidates: their synthesis and use
US6998484B2 (en) 2000-10-04 2006-02-14 Santaris Pharma A/S Synthesis of purine locked nucleic acid analogues
US6565808B2 (en) 2001-05-18 2003-05-20 Acon Laboratories Line test device and methods of use
US20110009960A1 (en) 2001-11-16 2011-01-13 Allergan, Inc. Prosthetic fabric structure
US6902932B2 (en) 2001-11-16 2005-06-07 Tissue Regeneration, Inc. Helically organized silk fibroin fiber bundles for matrices in tissue engineering
US6878805B2 (en) 2002-08-16 2005-04-12 Isis Pharmaceuticals, Inc. Peptide-conjugated oligomeric compounds
AU2003291755A1 (en) 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
JP2006519616A (ja) * 2003-03-03 2006-08-31 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ チロシンホスファターゼ−ｐｒｌ−１、膵臓癌のマーカーおよび治療標的
JP4731324B2 (ja) 2003-08-28 2011-07-20 武 今西 Ｎ−ｏ結合性架橋構造型新規人工核酸
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
ITVI20050059A1 (it) * 2005-03-04 2006-09-05 Consorzio Per Gli Studi Universitari In Verona Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali
WO2007033167A2 (en) * 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Compositions and methods for detecting and treating cancer
US7399845B2 (en) 2006-01-27 2008-07-15 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
ES2420834T3 (es) * 2006-01-30 2013-08-27 The Scripps Research Institute Métodos de detección de células tumorales circulantes y métodos de diagnóstico del cáncer en un sujeto mamífero
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
WO2008061091A2 (en) 2006-11-13 2008-05-22 Grandis Jennifer R Antisense guanidinium peptide nucleic acid (gpna) oligonucleotides as antitumor agents
EP2139430B1 (en) 2007-03-20 2019-06-05 Serica Technologies, Inc. Tendon prosthesis and method of manufacturing the same
CA2713667A1 (en) * 2008-01-31 2009-08-06 Compugen Ltd. Cd55 isoform and uses therof in cancer detection, monitoring and therapy
EP3708682B1 (en) * 2008-02-01 2022-11-23 The General Hospital Corporation Use of microvesicles in diagnosis and prognosis of medical diseases and conditions
EP2335075A4 (en) * 2008-09-05 2011-12-14 Scripps Research Inst METHOD FOR DETECTING CIRCULATING TUMOR CELLS
EP2326656B1 (en) 2008-09-06 2017-01-25 Chemgenes Corporation Rna synthesis - phosphoramidites for synthetic rna in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic rna at the 3' - end
US20110020221A1 (en) * 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
US20110256155A1 (en) * 2010-04-16 2011-10-20 Medimmune, Llc Methods to molecularly characterize circulating tumor cells
US20120100560A1 (en) * 2010-07-23 2012-04-26 The Johns Hopkins University Device for capture, enumeration, and profiling of circulating tumor cells
JP2014526032A (ja) * 2011-06-07 2014-10-02 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 癌に対する循環バイオマーカー
WO2013020139A1 (en) * 2011-08-04 2013-02-07 Iv Diagnostics, Llc Aptamer for the capture, diagnosis, enumeration, and eradication of circulating tumor cells
AU2014364520B2 (en) * 2013-12-20 2020-01-02 The General Hospital Corporation Methods and assays relating to circulating tumor cells
US9579673B2 (en) 2014-06-09 2017-02-28 The Procter & Gamble Company Flushing dispensers for delivering a consistent consumer experience
PL3707510T3 (pl) * 2017-11-06 2024-09-30 F. Hoffmann-La Roche Ag Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006029A1 (en) * 2001-07-13 2003-01-23 The University Of Sydney Method of inducing apoptosis in cancer cells
WO2006089091A2 (en) * 2005-02-18 2006-08-24 Memorial Sloan-Kettering Cancer Center Methods for detecting minimum residual disease
WO2009051734A1 (en) * 2007-10-17 2009-04-23 The General Hospital Corporation Microchip-based devices for capturing circulating tumor cells and methods of their use
WO2011112903A2 (en) * 2010-03-11 2011-09-15 Board Of Regents, The University Of Texas System Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
US20120009582A1 (en) * 2010-07-07 2012-01-12 The Regents Of The University Of Michigan Diagnosis and treatment of breast cancer
WO2013109944A1 (en) * 2012-01-18 2013-07-25 The Trustees Of The University Of Pennsylvania Methods for assessing risk for cancer using biomarkers
WO2013117705A1 (en) * 2012-02-09 2013-08-15 Var2 Pharmaceuticals Aps Targeting of chondroitin sulfate glycans
WO2013134649A1 (en) * 2012-03-09 2013-09-12 Verastem, Inc. Biomarkers for cancer stem cells and related methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SEUNG BAE RHO et al. Insulin-like growth factor-binding protein-5 (IGFBP-5) acts as a tumor suppressor by inhibiting angiogenesis. CARCINOGENESIS, 2008, vol. 29, No. 11, pages 2106-2111 *
SIEUWERTS, Anieta M et al., mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients. Clinical Cancer Research, 2011 v17(11) pages 3600-3618 *
ZALATNAI, Attila et al., Molecular Background of Chemoresistance in Pancreatic Cancer. in vivo, 1 January 2007, Retrieved from the Internet: URL:http://iv.iiarjournals.org/content/21/2/339.full.pdf *

Also Published As

Publication number Publication date
US10900083B2 (en) 2021-01-26
AU2020200114A1 (en) 2020-01-30
CN106456694B (zh) 2020-06-30
AU2020200114B2 (en) 2022-01-06
CN106456694A (zh) 2017-02-22
EP3082840A1 (en) 2016-10-26
JP6912538B2 (ja) 2021-08-04
WO2015095527A1 (en) 2015-06-25
JP7330235B2 (ja) 2023-08-21
JP2017503488A (ja) 2017-02-02
CN111729090A (zh) 2020-10-02
EP3082840A4 (en) 2017-11-22
AU2014364520A1 (en) 2016-07-07
JP2020022469A (ja) 2020-02-13
US20160312298A1 (en) 2016-10-27
EP3082840B1 (en) 2021-03-24
CA2934344A1 (en) 2015-06-25
JP6599334B2 (ja) 2019-10-30
JP2021168674A (ja) 2021-10-28
EP3865144A1 (en) 2021-08-18
US20210130910A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
AU2020200114B2 (en) Methods and assays relating to circulating tumor cells
US20160041153A1 (en) Biomarker compositions and markers
US20140220580A1 (en) Biomarker compositions and methods
US20110223616A1 (en) HuR-Associated Biomarkers
AU2012294458A1 (en) Biomarker compositions and methods
US20230119171A1 (en) Biomarker panels for stratification of response to immune checkpoint blockade in cancer
US20170198359A1 (en) Methods and compositions for treatment or diagnosis of cancers related to gabra3
CN106222259B (zh) 一种诊治多发性骨髓瘤的分子标志物
US20120156681A1 (en) Composition for diagnosis of liver metastasis of colorectal cancer and the use thereof
CN106011291B (zh) 一种诊治下咽癌的分子标志物
CN106119399B (zh) Znf385c作为下咽癌诊治标志物的用途
US20250002918A1 (en) Compositions and methods for treatment of mic60 depleted cancers and metastasis
US20240158871A1 (en) Pan-Cancer Classification Based on FMRP Pathway Activity that Informs Differential Prognosis and Therapeutic Responses
KR20250134312A (ko) 암　관련 섬유아세포를 이용한 암 진단 또는 치료 방법
CN106119400B (zh) C2cd4c在制备诊治下咽癌产品中的应用
KR20230062435A (ko) 면역억제물질 예측용 유전자 집단의 선별방법 및 이를 이용한 면역억제능 평가방법
CN111455049A (zh) LncRNA MEG3和MALAT1作为诊断胆囊癌的标志物的应用及其检测试剂盒

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ TING, DAVID T.; HABER, DANIEL A. AND MAHESWARAN, SHYAMALA

FGA Letters patent sealed or granted (standard patent)